Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Citi
US Army
Johnson and Johnson
US Department of Justice
Argus Health
AstraZeneca
Cipla
Accenture

Generated: July 17, 2018

DrugPatentWatch Database Preview

INTRALIPID 20% Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Intralipid 20%, and when can generic versions of Intralipid 20% launch?

Intralipid 20% is a drug marketed by Fresenius and is included in two NDAs.

The generic ingredient in INTRALIPID 20% is soybean oil. There are thirteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the soybean oil profile page.
Summary for INTRALIPID 20%
Drug patent expirations by year for INTRALIPID 20%
Pharmacology for INTRALIPID 20%
Ingredient-typeLipids
Drug ClassLipid Emulsion

US Patents and Regulatory Information for INTRALIPID 20%

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius INTRALIPID 20% soybean oil INJECTABLE;INJECTION 018449-001 Approved Prior to Jan 1, 1982 AP RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Fresenius INTRALIPID 20% soybean oil INJECTABLE;INJECTION 020248-001 Aug 7, 1996 AP RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Argus Health
McKesson
Johnson and Johnson
Queensland Health
Harvard Business School
Express Scripts
Daiichi Sankyo
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.